Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that the U.S. District Court for the Western District of Washington issued an order providing for preliminary approval of a proposed settlement of the claims asserted nominally on behalf of Athira against the individual defendants named in the previously disclosed stockholder derivative actions entitled Bushansky v. Kawas et al. No. 2:22-cv-497 and Houlihan v. Kawas et al ., No. 2:22-cv-620, pending before the court. The proposed settlement calls for Athira to adopt certain corporate governance reforms and pay lead plaintiffs' attorney's fees, litigation expenses, and lead plaintiff service awards.

The order set a final approval hearing for Thursday, July 18, 2024, at 10:30 am. As required by the order, the following materials have been posted to the Investor Relations section of Athira's website ( http://investors.athira.com/ ): the Zoom meeting information for the final approval hearing, the Stipulation of Settlement, a Summary Notice of Proposed Settlement of Stockholder Derivative Action, and a Notice of Proposed Settlement of Derivative Actions, Final Approval Hearing, and Right to Appear.

About Athira Pharma, Inc.
Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological diseases by advancing its pipeline of therapeutic candidates that modulate the neurotrophic HGF system, including fosgonimeton, which is being evaluated for the potential treatment of mild-to-moderate Alzheimer's disease in the Phase 2/3 LIFT-AD trial that is expected to report topline data in the second half of 2024. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on X, (formerly known as Twitter ) , and Instagram.

Investor & Media Contact:
Julie Rathbun
Athira Pharma
Julie.rathbun@athira.com
206-769-9219


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ATHA
The Conversation (0)
Athira Pharma Inc.

Athira Pharma Inc.

Athira Pharma Inc is a biotechnology company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The company is developing treatments for Alzheimer's disease and Parkinson's disease.

Stallion Uranium Announces Grant of Options

Stallion Uranium Announces Grant of Options

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Stallion Uranium Corp. (the " Company " or " Stallion " ) ( TSX-V: STUD ; OTCQB: STLNF ; FSE: FE0 ) is pleased to announce that under the Company's stock option plan dated October 8, 2024 (the " Plan "), the Company has granted a total of 3,100,000 stock options (" Options ") to certain directors, officers and consultants of the Company.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Stallion Uranium Completes Second and Final Tranche of Oversubscribed $15,000,000 Non-Brokered Private Placement

Stallion Uranium Completes Second and Final Tranche of Oversubscribed $15,000,000 Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Stallion Uranium Corp. (the " Company " or " Stallion " ) ( TSX-V: STUD ; OTCQB: STLNF ; FSE: FE0 ) is pleased to announce that it has closed a second and final tranche of its previously announced non-brokered private placement of units and flow-through units (the " Offering "). This closing consisted of 22,305,600 units of the Company (each a " NFT Unit ") at a price of $0.20 per NFT Unit for aggregate gross proceeds of $4,461,120 and 30,139,600 flow-through units (each a " FT Unit ") at a price of $0.20 per FT Unit for aggregate gross proceeds of $6,027,920.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Stallion Uranium Completes First Tranche of Non-Brokered Private Placement and Announces Upsizing

Stallion Uranium Completes First Tranche of Non-Brokered Private Placement and Announces Upsizing

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Stallion Uranium Corp. (the " Company " or " Stallion ") ( TSX-V: STUD ; OTCQB: STLNF ; FSE: FE0 ) is pleased to announce that it has closed a first tranche of its previously announced non-brokered private placement of units and flow-through units (the " Offering "). This closing consisted of 21,239,800 units of the Company (each a " NFT Unit ") at a price of $0.20 per NFT Unit for aggregate gross proceeds of $4,247,960 and 1,315,000 flow-through units (each a " FT Unit ") at a price of $0.20 per FT Unit for aggregate gross proceeds of $263,000.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Stallion Uranium Announces Flow-Through and Non-Flow Through Private Placements for Gross Proceeds of up to $12M

Stallion Uranium Announces Flow-Through and Non-Flow Through Private Placements for Gross Proceeds of up to $12M

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Stallion Uranium Corp. (the " Company " or " Stallion ") ( TSX-V: STUD; OTCQB: STLNF; FSE: FE0 ) is pleased to announce that it has arranged a non-brokered private placement (the " Offering ") of up to a combined aggregate of 60,000,000 flow-through (" FT Units ") and non-flow through (" NFT Units ") units at a price of $0.20 per NFT Unit and FT Unit for aggregate gross proceeds of up to $12,000,000. The Offering is expected to close in multiple tranches, the first of which is anticipated to close on or before August 15, 2025. The Company anticipates that, upon completion of the Offering, a new Control Person (as defined below), Mr. Matthew Mason (" Mr. Mason "), will be created though Mr. Mason's anticipated purchase of 15,000,000 FT Units. Mr. Mason's subscription is subject to obtaining requisite approval from the disinterested shareholders of the Company (as further described below) and the TSX Venture Exchange (the " TSXV ").

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Stallion Uranium Announces Update to Previously Announced Technology Licensing Agreement

Stallion Uranium Announces Update to Previously Announced Technology Licensing Agreement

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Stallion Uranium Corp. (the " Company " or " Stallion " ) ( TSX-V: STUD ; OTCQB: STLNF ; FSE: FE0 ) further to its news release of July 8 th 2025, the Company provides certain updates in respect of its technology licensing agreement dated July 7 th 2025 (the " Technology Licensing Agreement "), amongst the Company and Matthew J. Mason (the " Lessor "). The Lessor holds the exclusive license to certain proprietary technology and know-how that can be used to assist in area prioritization selection for the purposes of exploration for minerals (the " Technology "), which was developed by an arm's length Ph.D. geologist (the " Licensor ").

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and MagSense® HER2 Breast Cancer diagnostic imaging program, supporting the planned Phase 2 Clinical Trial expected to commence towards the end of 2025.

Keep reading...Show less
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare.

But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no indication that US hospitals are stockpiling equipment ahead of expected price hikes, according to recent findings from GlobalData.

Keep reading...Show less
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This establishes the timeline for the planned safety and efficacy futility interim analysis by an independent Data Monitoring Committee (DMC).

Keep reading...Show less
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access Emyria’s Empax PTSD care program delivered in association with Perth Clinic.

Keep reading...Show less
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will integrate HITIQ’s PROTEQT technology. The result is a fully developed, market-ready solution that merges HITIQ’s smart sensor technology with Shock Doctor’s unmatched global production partner capabilities.

Keep reading...Show less
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Keep reading...Show less

Latest Press Releases

Related News

×